Display options
Cite
O'Brian K, Luo S, Ganti A, et al. Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Leuk Lymphoma. 2015;57(2):313-319doi: 10.3109/10428194.2015.1056183.
O'Brian, K., Luo, S., Ganti, A., Riedell, P., Lynch, R. C., Roop, R., Sanfilippo, K. M., Liu, W., Colditz, G. A., & Carson, K. R. (2016). Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Leukemia & lymphoma, 57(2), 313-319. https://doi.org/10.3109/10428194.2015.1056183
O'Brian, Katiuscia, et al. "Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy." Leukemia & lymphoma vol. 57,2 (2016): 313-319. doi: https://doi.org/10.3109/10428194.2015.1056183
O'Brian K, Luo S, Ganti A, Riedell P, Lynch RC, Roop R, Sanfilippo KM, Liu W, Colditz GA, Carson KR. Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Leuk Lymphoma. 2016 Feb;57(2):313-319. doi: 10.3109/10428194.2015.1056183. Epub 2015 Jul 25. PMID: 26085202; PMCID: PMC4752439.
Copy Download .nbib Format: NLM
Share it on

Leuk Lymphoma. 2016 Feb;57(2):313-319. doi: 10.3109/10428194.2015.1056183. Epub 2015 Jul 25.

Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapy.

Leukemia & lymphoma

Katiuscia O'Brian, Suhong Luo, Arun Ganti, Peter Riedell, Ryan C Lynch, Ryan Roop, Kristen M Sanfilippo, Weijian Liu, Graham A Colditz, Kenneth R Carson

Affiliations

  1. a Research Service, St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.
  2. b Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA.
  3. c Department of Emergency Medicine , University of Michigan Health System , Ann Arbor , MI , USA.
  4. d Division of Oncology, Department of Medicine , Stanford University School of Medicine/Stanford Cancer Institute , Stanford , CA , USA.
  5. e Northwest Oncology and Hematology, Kalispell Regional Medical Center , Kalispell , MT , USA.
  6. f Division of Public Health Sciences, Department of Surgery , Washington University School of Medicine , St. Louis , MO , USA.

PMID: 26085202 PMCID: PMC4752439 DOI: 10.3109/10428194.2015.1056183

Abstract

Identifying weight changes associated with treatment of diffuse large B-cell lymphoma (DLBCL) has the potential to improve the long-term health of survivors. A retrospective cohort of United States veterans with a new diagnosis of DLBCL between October 1, 1998 and September 30, 2008, with follow-up until April 23, 2013, was assembled. Weight changes were evaluated before, during, and after treatment in 1935 DLBCL patients who received cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab (CHOP+/- R). One year prior to treatment, 79% of patients were obese or overweight. During the 12 months leading up to treatment, 57% of the cohort lost weight. Among patients surviving 24 months after treatment initiation, weight increased an average of 2.9 kg above weight at treatment completion. The weight change trends observed in these DLBCL patients suggest that weight management strategies may be an important part of long-term survivorship planning after conclusion of treatment.

Keywords: CHOP chemotherapy; lymphoma; veterans; weight change

References

  1. Blood. 2007 Jul 15;110(2):695-708 - PubMed
  2. Leuk Lymphoma. 2012 Apr;53(4):569-74 - PubMed
  3. Obes Rev. 2001 Nov;2(4):219-29 - PubMed
  4. J Clin Oncol. 2005 Aug 1;23(22):4980-90 - PubMed
  5. Br J Cancer. 2006 Apr 10;94(7):1011-5 - PubMed
  6. Oncologist. 2010;15(6):556-65 - PubMed
  7. J Clin Oncol. 2014 Jul 20;32(21):2231-9 - PubMed
  8. Eur J Clin Nutr. 2004 Jan;58(1):137-44 - PubMed
  9. Epidemiol Rev. 2007;29:6-28 - PubMed
  10. Nutr Cancer. 2013;65(1):43-50 - PubMed
  11. Anticancer Res. 1999 Nov-Dec;19(6C):5607-10 - PubMed
  12. N Engl J Med. 2011 Jun 23;364(25):2392-404 - PubMed
  13. Oncologist. 2000;5(3):238-49 - PubMed
  14. N Engl J Med. 2006 Aug 24;355(8):763-78 - PubMed
  15. J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90 - PubMed
  16. Clin Breast Cancer. 2011 Mar;11(1):52-60 - PubMed
  17. N Engl J Med. 2002 Jan 24;346(4):235-42 - PubMed
  18. J Clin Oncol. 2009 Sep 20;27(27):4605-12 - PubMed
  19. Am J Prev Med. 2003 May;24(4):332-9 - PubMed
  20. Br J Cancer. 2003 Jan 13;88(1):36-41 - PubMed
  21. Urology. 2004 Apr;63(4):742-5 - PubMed
  22. Int J Obes Relat Metab Disord. 2002 Feb;26(2):241-6 - PubMed
  23. J BUON. 2010 Apr-Jun;15(2):290-6 - PubMed
  24. Int J Cancer. 2008 May 1;122(9):2062-70 - PubMed
  25. J Clin Oncol. 2014 Jun 10;32(17):1840-50 - PubMed
  26. Lancet. 2008 Feb 16;371(9612):569-78 - PubMed
  27. Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):388-95 - PubMed

Publication Types

Grant support